Do four SGLT2 inhibitors lead to different cardiorenal benefits in type 2 diabetes, in chronic heart failure, and in chronic kidney disease?
Do four SGLT2 inhibitors lead to different cardiorenal benefits in type 2 diabetes, in chronic heart failure, and in chronic kidney disease?
Eur J Intern Med. 2021 Jan 20;:
Authors: Qiu M, Ding LL, Zhan ZL, Zhou HR
PMID: 33485738 [PubMed - as supplied by publisher]
Source: European Journal of Internal Medicine - Category: Internal Medicine Authors: Qiu M, Ding LL, Zhan ZL, Zhou HR Tags: Eur J Intern Med Source Type: research
More News: Cardiology | Chronic Kidney Disease | Diabetes | Diabetes Type 2 | Endocrinology | Heart | Heart Failure | Internal Medicine | Science | SGLT2 Inhibitors | Urology & Nephrology